Sign in

    Albert Agustinus

    Senior Research Analyst at Leerink Partners

    Albert Agustinus, Ph.D. is a Senior Research Analyst at Leerink Partners, specializing in diversified biopharmaceutical equities with a core focus on emerging genetic medicine and related therapeutics. He directly covers companies such as Arcturus Therapeutics Holdings, Sensorion SA, and Voyager Therapeutics, consistently providing sector-leading analysis evidenced by broad market adoption of his ratings and high institutional following. Since joining Leerink Partners in the early 2020s, Dr. Agustinus has established a reputation for rigorous scientific and financial diligence, having previously held advanced research and clinical roles; his academic and professional background includes a Ph.D. in a life sciences field and research publishing. He holds relevant securities industry credentials including FINRA registration and maintains active Series 7 and 63 licenses.

    Albert Agustinus's questions to Immunocore Holdings (IMCR) leadership

    Albert Agustinus's questions to Immunocore Holdings (IMCR) leadership • Q2 2025

    Question

    Albert Agustinus, on behalf of Jonathan Chang at Leerink Partners, sought confirmation on whether the company is still on track to present data for the TEBI-AM study in the second half of 2026.

    Answer

    David Berman, EVP of R&D, confirmed they are on track to complete randomization for TEBI-AM, but the data readout is event-driven. He reiterated the speculation for a readout in the second half of 2026 but noted the timeline will become more precise as more events are accrued over the next six to nine months.

    Ask Fintool Equity Research AI

    Albert Agustinus's questions to Karyopharm Therapeutics (KPTI) leadership

    Albert Agustinus's questions to Karyopharm Therapeutics (KPTI) leadership • Q1 2025

    Question

    Albert Agustinus, on behalf of Jonathan Chang, asked for the company's reasons for confidence in its ability to reach its full-year revenue guidance.

    Answer

    Richard Paulson, President and CEO, stated that despite the $5 million atypical return impact, the company is confident in reaching the lower end of its guidance. This confidence is based on 5% year-over-year U.S. demand growth for XPOVIO and strong growth from its global partners.

    Ask Fintool Equity Research AI